In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 5, 1999, Pages 697-700

  Chavez M ^a   Bernal, S ^a   Valverde, A ^a   Gutierrez, M J ^a   Quindos G ^b   Mazuelos, E Martin ^a  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; CANDIDA; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, ORAL; MICROBIAL SENSITIVITY TESTS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 0345201630     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.5.697     Document Type: Article

References (10)

1. Barry, A. L. & Brown, S. D. (1996). In vitro studies of two triazole antifungal agents (Voriconazole [UK-109,496] and Fluconazole) against Candida species. Antimicrobial Agents and Chemotherapy 40, 1948-9.
2. Schwartz, S., Milatovic, D. & Thiel, E. (1997). Succesful treatment of cerebral aspergillosis with a novel triazole (voriconazole), in a patient with acute leukaemia. British Journal of Haematology 97, 663-5.
3. Denning, D. W. (1997). Echinocandins and pneumocandins, a new antifungal class with a novel mode of action. Journal of Antimicrobial Chemotherapy 40, 611-4.
4. Marco, F., Pfaller, M. A., Messer, S. & Jones, R. N. (1998). In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrobial Agents and Chemotherapy 42, 161-3.
5. Murphy, M., Bernard, E. M., Ishimaru, T. & Armstrong, D. (1997). Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 41, 696-8.
6. Ruhnke, M., Schmidt-Westhausen, A. & Trautmann, M. (1997). In vitro activities of voriconazole (UK-109,496) against fluconazole susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection. Antimicrobial Agents and Chemotherapy 42, 575-82.
7. National Comittee for Clinical Laboratory Standards. (1997). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts - Approved Standard M27-A. NCCLS, Villanova, PA.
8. Espinel-Ingroff, A. (1998). In vitro activity of the new triazole voriconazole (UK-109,496) against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens. Journal of Clinical Microbiology 36, 198-202.
9. Krishnarao, T. V. & Galgiani, J. N. (1997). Comparison of the in vitro activities of the echinocandine LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrobial Agents and Chemotherapy 41, 1957-60.
10. Uzun, Ö., Kocagöz, S., Çetinkaya, Y., Arikan, S. & Ünal, S. (1997). In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrobial Agents and Chemotherapy 41, 1156-7.